Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients

Serretta, Vincenzo; Presti, Domenico Lo; Vasile, P.; Gange, E.; Espósito, Elisa; Menozzi, I.

doi:10.1016/s0090-4295(98)00332-x

Cited by 46 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This might be explained by the fact that the cytology test distingushes between inflammatory and malignant alterations in urothelial cells; however, the physician must be experienced. Our results underline the data reported by Serretta et al [14] who also found a low specificity of the NMP 22 test.…”

Section: Discussionsupporting

confidence: 91%

Comparison of Cytology and Nuclear Matrix Protein 22 for the Detection and Follow-Up of Bladder Cancer

et al. 2001

View full text Add to dashboard Cite

Objectives: This study was designed to determine the clinical usefulness of the nuclear matrix protein 22 (NMP 22) test for the detection of bladder cancer in comparison to urine cytology. Methods: 84 patients suffering from bladder cancer or suspected bladder cancer, 25 patients with benign urological lesions and 60 healthy controls participated in a prospective study. Freshly voided spot urine samples were taken for cytological examination and determination of NMP 22 levels by enzyme-linked immunoassay. Results: The sensitivity of the NMP 22 test according to the tumor grading was (results of cytology in brackets): G1 25.0% (20.0%); G2 68.2% (59.1%), and G3 100.0% (66.7); overall sensitivity was 62.5% (45.0%). The sensitivity for superficial bladder cancer was 46.7% (36.7%) and for invasive bladder cancer 90.0% (70.0%). The specificity was 65.9% (88.9%). Conclusions: NMP 22 is a reliable tool for detecting invasive bladder cancer. Results for the frequently occurring low grade superficial bladder cancer are as poor as those obtained with cytology. In addition benign lesions such as urolithiasis or urinary tract infection lead to false-positive results. Therefore cystoscopy has to be performed when trying to detect and follow-up bladder cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

Comparison of Cytology and Nuclear Matrix Protein 22 for the Detection and Follow-Up of Bladder Cancer

et al. 2001

View full text Add to dashboard Cite

show abstract

“…The optimal cutoff value varies according to authors: the one most used is 10 U/ml [12][13][14][15][16], though it ranges from 6 to 13.74 U/ml [17][18][19][20][21]. Due to the variability in this cutoff value, it is difficult to compare different series.…”

Section: Discussionmentioning

confidence: 99%

NMP 22, BTA stat Test and Cytology in the Diagnosis of Bladder Cancer: A Comparative Study

Baños

Rodrigo²,

Juárez³

et al. 2001

Urol Int

View full text Add to dashboard Cite

Objective: To evaluate the usefulness of the NMP 22 and BTA stat test in the diagnosis and follow-up of bladder cancer and to compare these tests to cytology and cystoscopy, routine diagnostic methods. Methods: 150 patients followed up for bladder cancer or symptoms suggestive of bladder cancer underwent cystoscopy after cytology, NMP 22 and BTA stat test using a recently voided urine sample. In suspect cases, TUR and histopathological analysis were performed. Results: Bladder cancer was proven in 76 patients and excluded in 74. For NMP 22 we have used the cutoff value recommended by the manufacturer (10 U/ml) and that obtained by our receiver-operating characteristic curve (6 U/ml). Sensitivity was 84.21% for NMP 22 at the cutoff value of 6 U/ml and 76.32% with 10 U/ml; 72.37% for BTA stat test; 69.74% for cytology, and 100% for cystoscopy. Specificity was 86.49% for NMP 22 at a cutoff value of 6 U/ml and 90.54% at 10 U/ml; 89.19% for the BTA stat test; 93.24% for cytology and 89.19% for cystoscopy. NMP 22 sensitivity for grades 1, 2, and 3 was 68.75, 75.86 and 100%, respectively, at a cutoff value of 6 U/ml, and 50, 68.97 and 96.77%, respectively, at a cutoff level of 10 U/ml; for BTA stat the sensitivity was 56.25% in G1, 62.07% in G2 and 90.32% in G3, and for cytology the sensitivity was 43.75, 62.07 and 90.32%, respectively. The sensitivity of NMP 22 was 68.75% in stage Ta, 84.78% in T1 and 100% in T2–T4 at a cutoff level of 6 U/ml and 50, 80.43 and 92.86%, respectively, at a cutoff level of 10 U/ml; BTA stat sensitivity was 50% in Ta, 73.91% in T1 and 92.86% in T2–T4; and in cytology the results were 37.50, 73.91 and 85.71%, respectively. Using the McNemar test, there was only a significant difference between the sensitivity of NMP 22 at a cutoff level of 6 U/ml and cytology in the overall sample. Conclusions: The high sensitivity of the NMP 22 and BTA stat test in combination with the data obtained from the parameters used for the evaluation of the test demonstrate their usefulness in the diagnosis and follow-up of bladder cancer. NMP 22 at a cutoff value of 6 U/ml is significantly more sensitive than cytology and consequently a thoroughly valid diagnostic tool in the diagnosis of bladder cancer which may substitute voided urine cytology.

show abstract

“…26,27 To explore the feasibility of urine sample as a source of tumour cells for the determination of gene expression signature, HOXA13-BLCA-4 (uRNA-S) was used. Given the known inaccuracy in discriminating BTCC of stage Ta from those of stage T1 with clinical utility, 28 the actual accuracy of uRNA-S for the prediction of stages may exceed that which was observed here.…”

Section: Discussionmentioning

confidence: 99%

Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray

Guo

Che

Shi³

et al. 2013

CUAJ

View full text Add to dashboard Cite

Objective: The objective of this study was to screen and identify differentially expressed genes in invasive bladder transitional cell carcinoma (BTCC). Methods: Voided urine samples were collected from consecutive patients with BTCC and patients under surveillance for bladder cancer recurrence; voided urine samples from patients with nonmalignant diseases served as control. We identified the differentially expressed genes by comparing urine samples of bladder carcinoma to that of the control group with suppressive subtractive hybridization (SSH) and cDNA microarray. The differentially expressed genes were verified by quantitative real-time polymerase chain reaction (QPCR). Results: From the 762 white colonies, a total of 449 positive clones were obtained in which 112 were found to be upregulated in BTCC. Sequencing and homology analysis were performed for these 112 clonies. The detection rates of some known genes (including IGF-1, human telomerase reverse transcriptase [hTERT], bladder cancer specific nuclear matrix protein 4 [BLCA-4] and homeobox A13 [HOXA13]) for BTCC at the Ta, T1 and >T1 stages were 48%, 90% and 100%, respectively, with a specificity of 85%. The test specificity was 80% for the 30 control patients with urinary tract infections. The combination of BLCA-4 and HOXA13 could distinguish between low-and high-grade tumours, with specificity and sensitivity of 80%. Conclusion: We successfully constructed a reliable SSH library of BTCC and found that combination detection insulin-like growth factor 1 (IGF-1), hTERT, BLCA-4 and HOXA13 genes could help to evaluate BTCC at different stages. IntroductionBladder transitional cell carcinoma (BTCC) is the fourth common cancer worldwide.1 The 5-year relative survival rate is about 6% for patients with an advanced stage of bladder cancer.1 Cystoscopy and biopsy of suspected lesions have been regarded as the gold standard in the diagnosis of bladder cancer and in the follow-up of these patients. A variety of studies have focused on developing new non-invasive methods for the diagnosis of bladder cancer and monitoring the progression of the disease. New biomarkers that would increase the detection rate of transitional cell carcinomas (TCCs) before bladder muscle layer invasion would reduce TCC-related morbidity and mortality. Although the detection of telomerase and hyaluronic acid phyaluronidase in the urine is sensitive and specific, their role in bladder cancer still requires validation through multicentre clinical studies.2 Therefore, it is important to find the specific biomarkers for bladder cancer which may improve the early diagnosis and effective postoperative follow-up.Recent studies using high-throughput microarray analysis have shown that cDNA expression is helpful in discriminating bladder tumours from normal urothelium at different stages or grades.3,4 The detection of gene expression in the urine may be promising in the diagnosis of TCC and would provide more information for clinical practice. With the rapid development of molecular biot...

show abstract

Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients

Cited by 46 publications

References 10 publications

Comparison of Cytology and Nuclear Matrix Protein 22 for the Detection and Follow-Up of Bladder Cancer

Comparison of Cytology and Nuclear Matrix Protein 22 for the Detection and Follow-Up of Bladder Cancer

NMP 22, BTA stat Test and Cytology in the Diagnosis of Bladder Cancer: A Comparative Study

Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray

Contact Info

Product

Resources

About